Clinical Trial Update: Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) [Phase 3]

View source ↗

Summary

This Phase 3 trial (MK-3475-177/KEYNOTE-177) compares pembrolizumab to standard therapy in MSI-H/dMMR stage IV colorectal cancer. Results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Colorectal Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2022-03-16